In the Claims

Please amend the claims as follows:

1-24. (Cancelled)

25. (Currently Amended) A method of relieving a CEA/NCA-imposed inhibition of differentiation, and/or CEA/NCA-imposed apoptosis, and/or CEA/NCA-imposed distortion of tissue architecture comprising an incubation of primary or secondary tumor cells with an ~~agent~~ anti-CEA/NCA antibody which disrupts ~~one of an~~ a CEA/NCA interaction ~~between CEA/NCA subdomains having sequences selected from G[30]YSWYK (SEQ ID NO: 1), N[42]RQII (SEQ ID NO: 2,), and Q[80]ND (SEQ ID NO: 25)0, and a functional interaction between said subdomains and integrin $\alpha_5\beta_1$ and $\alpha_v\beta_3$~~ involving a N-terminal domain of CEA/NCA as set forth between amino acids 1 to 107 of SEQ ID NO:5, thereby relieving a CEA/NCA-imposed inhibition of differentiation, and/or CEA/NCA-imposed apoptosis, and/or CEA/NCA-imposed distortion of tissue architecture.

26. (New) The method of claim 25, wherein said antibody disrupts a CEA/NCA interaction which involves an interaction of amino acid at positions 30 to 82 of SEQ ID NO: 5.

27. (New) The method of claim 26, wherein said antibody disrupts a CEA/NCA interaction which involves an interaction of amino acid at positions 30 to 46 of SEQ ID NO: 5.

28. (New) The method of claim 26, wherein said antibody disrupts a CEA/NCA interaction which involves an interaction of at least one of

a) amino acid positions 30 to 35 of SEQ ID NO: 5 (SEQ ID NO: 1);
b) amino acid positions 42 to 46 of SEQ ID NO: 5 (SEQ ID NO: 2); and
c) amino acid positions 80 to 82 of SEQ ID NO: 5 (SEQ ID NO: 25).

29. (New) The method of claim 25, further comprising an incubation of said primary or secondary tumor cells with a cytotoxic agent.

30. (New) The method of claim 25, wherein said antibody is a monoclonal antibody.